effectiveness of Mulnopiravir, Paxlovid and Floxamine in the treatment of patients with Covid-19: A review study

since 2021, one of the most important global public health challenges has been the COVID-19 coronavirus pandemic. Three of the drugs that have been introduced to treat patients with COVID-19 in mild to moderate stage include paxlovid, molnopyravir and fluoxamine. The aim of this study was to evaluate the effectiveness of these drugs in the treatment of patients with COVID-19 in mild to moderate stage.

This study was done through umbrella review and in order to conduct a systematic review in PubMed, CoChrane and Google Scholar databases with appropriate vocabulary. The articles were evaluated for quality using the CASP checklist. The study extracted outcomes related to the drugs, such as hospitalization and death rates due to COVID-19, as well as any side effects reported in the studies.

Based on the findings, Paxlovid reduced the risk of death and the likelihood of hospitalization by about 88% while fluvoxamine reduced the likelihood of hospitalization by about 31%. The use of Molnopyravir reduces the risk of hospitalization or death by about 30%. However, the efficacy of this drug decreased with the expansion of the omecaron strain.

Paxlovid drug is effective in reducing the possibility of hospitalization and mortality of patients with covid-19 in the mild to moderate stage. However, regarding the effectiveness of Molnopiravir and Fluxamine, the level of evidence is low and more research is needed.